OXURION NV – First Patient Dosed in Part B of Phase 2 KALAHARI Study Evaluating Multiple Administrations of THR-149 versus aflibercept for Treatment of Diabetic Macular Edema (DME)
THR-149 is a potent plasma kallikrein inhibitor for the treatment of DME in the roughly…
From Phase III Trials to Commercialization Partnerships, MindRank’s AI Drug Development Value Comes into Focus
TMX Group Equity Financing Statistics – September 2026
TMX Group Limited Announces Release Date for Q3 2026 Financial Results and Analyst Conference Call
GMG Announces 48% Increase in Energy Density, Doubling of Cycle Life and 94% Energy Efficiency for 6 Minute Fast Charge
DGTL Holdings Inc. Announces Failure-to-File Cease Trade Order